inv(16)(p13q22) CBFB/MYH11
t(16;16)(p13;q22) CBFB/MYH11
del(16)(q22) CBFB/MYH11
1999-06-01 Jean-Loup Huret  
Affiliation
1.Genetics, Dept Medical Information, University of Poitiers, CHU Poitiers Hospital, F-86021 Poitiers, France
Clinics and Pathology
Disease
acute non lymphoblastic leukaemia (AML); myelodysplastic syndromes (MDS) at times
Phenotype stem cell origin
nearly pathognomonic of M4eo-AML (all M4eo share the 16q22 anomaly -see also below-, but not all 16p13/16q22 are found in the M4eo subtype: i.e. this anomaly, although mainly found in M4-AML with marked eosinophilia, may (rarely) been found in : M2 or M5, M4 without eo, or in MDS; there are also known cases of chronic myelogenous leukaemia in blast crisis (BC-CML) with a M4 eo phenotype and inv(16); found at times in treatment related AML; 3 cases of infant leukaemia so far described; note: CD2 (T-cell marker) may be co-expressed
Epidemiology
5-10% of AML, 20% of M4
Clinics
CNS involvement is frequent, according to some authors, in particular at relapse
Cytology
most often: eosinophils > 5%, with large immature basophilic granules, NASCA+, in the bone marrow (but normal in blood: this M4 do not show the eo characteristic in blood)

Patients with inv(16) usually correspond to the subclass of AML M4, with a specific abnormal eosinophil component and is considered as a distinct entity in correlation with these specific chromosomal abnormalities. These cases of AML M4 are referred as AML M4EO. In addition to the morphological features of AML M4 excess of monocytes), the bone marrow shows a variable number of eosinophils at all stages of maturation without significant maturation arrest. The most striking abnormalities involve the immature eosinophilic granules. Those are mainly evident at the promyelocyte and myelocyte stages. The abnormalities are not usually evident at later stages of maturation. These eosinophilic granules are often larger than those normally seen in immature eosinophils, purple-violet in color and in some cells are so dense that they obscure the cell morphology - Text and iconography Courtesy Georges Flandrin 2001.
Prognosis
high CR rate; better prognosis than most other AML; median survival may be 5yrs
Cytogenetics
Cytogenetics morphological
may be overlooked, especially with R-banding; best seen without banding procedure (giemsa) for some workers
Cytogenetics molecular
with 16p13 probes : as a deletion within 16p13 often accompany the 16p13/16q22 rearrangement (in 20% of cases), the split signal may be lost
Additional anomalies
none 2/3 of cases; +8, +22 in 15% each, del(7q), +2; apparently without prognostic significance
Variants
are known:
1- t(16;16)(p13;q22);
- del(16)(q22): may be associated with less typical phenotype and preceding MDS, older age, complex karyotype, worse prognosis;
1- t(16;16)(p13;q22);
- del(16)(q22): may be associated with less typical phenotype and preceding MDS, older age, complex karyotype, worse prognosis;
2- but also: translocations of 16q22 with various partners in: t(1;16)(p31-32;q22), t(3;16)(q21;q22), t(5;16)(q33;q22), associated with eosinophils anomalies
Genes Involved and Proteins
Gene name
MYH11 (myosin heavy chain) (incomplete)
Location
16p13.11

c-MYH11 (16p13) in normal cells: PAC 1032E3 (top) and PAC 1179J13 (below) - Courtesy Mariano Rocchi, Resources for Molecular Cytogenetics.
Protein description
contains a N-term ATPase head responsible for actin binding and mechanical movement, and a C-term long repeat of coil-coil domain to facilitate filament aggregates; member of the myosin II family
Gene name
CBFB (subunit b of core binding factor)
Location
16q22.1
Protein description
subunit of the transcription factor complex CBF; CBFb by itself does not contain any DNA binding motif or transcriptional activation domain, but forms a dimer with CBFa: --> transcription factor
Result of the Chromosomal Anomaly
Description
5 CBFb - 3 MYH11; breakpoint in CBFB intron n° 5 and in MYH11 intron A (i.e. : 5)
Transcript
at least 8 different CBFb-MYH11 fusion transcripts have been described, transcript type A (with positions at nucleotides 495 and 1921 respectively) being found in about 90% of the patients;most braekpoints in MYH11 are also clustered; no reciprocal MYH11-CBFB transcript
Description
N-term - the first 165 (or 133 in a few cases) amino acids of CBFb, removing only 17 or 22 amino acids fused to the tail of MYH11 C-term with its multimerization domain; also variable breakpoint in MYH11; identical fusion protein in the cases of RAEBT and BC-CML
Expression localisation
nuclear localisation
Oncogenesis
the fusion protein seems both to diminuish the quantity of active CBF and to compete with it, there is accumulation of CBFb-MYH11/CBFa multimeres in the nucleus
Highly cited references
| Pubmed ID | Year | Title | Citations |
|---|---|---|---|
| 31817911 | 2019 | Core Binding Factor Leukemia: Chromatin Remodeling Moves Towards Oncogenic Transcription. | 150 |
| 34440157 | 2021 | How to Improve Prognostication in Acute Myeloid Leukemia with CBFB-MYH11 Fusion Transcript: Focus on the Role of Molecular Measurable Residual Disease (MRD) Monitoring. | 123 |
| 38061017 | 2023 | Proteogenomic analysis reveals cytoplasmic sequestration of RUNX1 by the acute myeloid leukemia-initiating CBFB::MYH11 oncofusion protein. | 112 |
| 32831296 | 2020 | CBFB-MYH11 fusion neoantigen enables T cell recognition and killing of acute myeloid leukemia. | 93 |
| 36874378 | 2023 | Therapy-related core binding factor acute myeloid leukemia. | 86 |
| 29755956 | 2018 | Preleukemia and Leukemia-Initiating Cell Activity in inv(16) Acute Myeloid Leukemia. | 81 |
| 34804441 | 2021 | Gastrointestinal Myeloid Sarcoma a Case Presentation and Review of the Literature. | 80 |
| 27798625 | 2016 | The genomic landscape of core-binding factor acute myeloid leukemias. | 79 |
| 40763310 | 2025 | CBFβ-SMMHC-driven leukemogenesis requires enhanced RUNX1-DNA binding affinity in mice. | 72 |
| 37019972 | 2023 | Etiology of oncogenic fusions in 5,190 childhood cancers and its clinical and therapeutic implication. | 71 |
| 34686664 | 2021 | Targeting miR-126 in inv(16) acute myeloid leukemia inhibits leukemia development and leukemia stem cell maintenance. | 70 |
| 34336831 | 2021 | CBFB-MYH11 Fusion Sequesters RUNX1 in Cytoplasm to Prevent DNMT3A Recruitment to Target Genes in AML. | 67 |
| 42933890 | 2026 | CBFB-MYH11 directly activates TGFβ and PD-L1 to drive immune evasion in acute myeloid leukemia. | 66 |
| 33730843 | 2022 | Clinical significance of RAS pathway alterations in pediatric acute myeloid leukemia. | 54 |
| 40829168 | 2025 | Proteomic subtypes enrich current acute myeloid leukemia nomenclature and reflect intrinsic pathogenesis alongside aging. | 52 |
| 35973983 | 2022 | Phenotypically-defined stages of leukemia arrest predict main driver mutations subgroups, and outcome in acute myeloid leukemia. | 52 |
| 33836581 | 2021 | Enhanced cytarabine-induced killing in OGG1-deficient acute myeloid leukemia cells. | 51 |
| 38936913 | 2024 | Molecular and Clinical Insights in the Increasing Detection of BCR::ABL1 p190+ in Adult Acute Myeloid Leukemia Patients. | 50 |
| 40156426 | 2025 | The Fusion Genes and Their Relation with Genetic Variants in Egyptian AML Patients. | 48 |
| 36442087 | 2022 | Transcriptome-based molecular subtypes and differentiation hierarchies improve the classification framework of acute myeloid leukemia. | 47 |
| 32929473 | 2020 | RUNX1 and CBFβ-SMMHC transactivate target genes together in abnormal myeloid progenitors for leukemia development. | 47 |
| 31624376 | 2020 | Gata2 deficiency delays leukemogenesis while contributing to aggressive leukemia phenotype in Cbfb-MYH11 knockin mice. | 46 |
| 39966122 | 2025 | Genetic abnormalities predict outcomes in patients with core binding factor acute myeloid leukemia. | 45 |
| 30742053 | 2019 | IL1RL1 is dynamically expressed on Cbfb-MYH11(+) leukemia stem cells and promotes cell survival. | 43 |
| 35251131 | 2022 | Fusion Gene Detection Using Whole-Exome Sequencing Data in Cancer Patients. | 43 |
| 41294667 | 2025 | Unveiling the Genetic Mosaic of Pediatric AML: Insights from Southwest China. | 43 |
| 37699001 | 2023 | Rapid detection of myeloid neoplasm fusions using single-molecule long-read sequencing. | 42 |
| 34771519 | 2021 | CBFB Break-Apart FISH Testing: An Analysis of 1629 AML Cases with a Focus on Atypical Findings and Their Implications in Clinical Diagnosis and Management. | 42 |
| 29018080 | 2017 | Chd7 deficiency delays leukemogenesis in mice induced by Cbfb-MYH11. | 41 |
| 31896782 | 2020 | The clinical mutatome of core binding factor leukemia. | 40 |
| 41300735 | 2025 | CBFB::MYH11 Fusion Located on a Supernumerary Ring Chromosome 16 in Pediatric Acute Myeloid Leukemia: Diagnostic Challenges and Prognostic Implications. | 39 |
| 35794567 | 2022 | Molecular dissection of a hyper-aggressive CBFB-MYH11/FLT3-ITD-positive acute myeloid leukemia. | 37 |
| 34547772 | 2021 | CBFB-MYH11 fusion transcripts distinguish acute myeloid leukemias with distinct molecular landscapes and outcomes. | 35 |
| 41173205 | 2026 | Cohesin haploinsufficiency is tolerated in Cbfb::MYH11-driven murine acute myeloid leukemia. | 35 |
| 38493200 | 2024 | Application of droplet digital PCR in minimal residual disease monitoring of rare fusion transcripts and mutations in haematological malignancies. | 34 |
| 36939402 | 2023 | Assessment of acute myeloid leukemia molecular measurable residual disease testing in an interlaboratory study. | 33 |
| 40304077 | 2025 | Clinical characteristics and therapeutic determinants of RUNX1::RUNX1T1 differ from those of CBFB::MYH11 acute myeloid leukemia. | 33 |
| 35497938 | 2022 | Therapy-related acute myeloid leukemia: A case series. | 30 |
| 39020534 | 2024 | Classic and molecular cytogenetic findings in leukemia patients from the Western part of Romania. | 23 |
| 34660293 | 2021 | Case Report: A Novel Activating FLT3 Mutation in Acute Myeloid Leukemia. | 20 |
| 20421454 | 2010 | Senescence induction in human fibroblasts and hematopoietic progenitors by leukemogenic fusion proteins. | 19 |
| 42533004 | 2026 | Venetoclax, azacitidine, and G-CSF targeting molecular residual disease in CBFB::MYH11 AML resistant to high-dose cytarabine. | 15 |
| 37225965 | 2023 | Characterization of leukemia progression in the Cbfb-MYH11 knockin mice by single cell RNA sequencing. | 14 |
| 41152985 | 2025 | Resolving intra-tumor heterogeneity and clonal evolution of core-binding factor acute myeloid leukemia patients with single-cell resolution. | 13 |
| 37591621 | 2023 | Core-binding factor abnormalities involving chromosome 16 in acute myeloid leukaemia: prognostic and therapeutic implications. | 11 |
| 22228403 | 2012 | Characteristics of translocation (16;16)(p13;q22) acute myeloid leukemia. | 10 |
| 34512985 | 2021 | Abnormal eosinophils with immature eosinophilic granules in chronic myeloid leukemia in accelerated phase. | 2 |
| 38153768 | 2023 | CBFB::MYH11 fusion in a nonmonocytic acute myeloid leukemia. | 0 |
| 22032582 | 2011 | Core-binding factor acute myeloid leukemia. | 0 |
| 35622005 | 2022 | AML with inv(16)/t(16;16) and high-risk cytogenetic abnormalities: atypical features and unfavorable outcome. | 0 |
| 32202250 | 2021 | Detection of del(16q) using the CBFB-MYH11 translocation dual fusion probe. | 0 |
| 36653696 | 2023 | Comprehensive molecular understanding of pediatric acute myeloid leukemia. | 0 |
| 19215983 | 2009 | Aleukemic bcr-abl positive granulocytic sarcoma. | 0 |
| 33162510 | 2020 | [Clinical significance of MRD in AML]. | 0 |
| 36039018 | 2022 | Mutual exclusivity between the fusion gene CBFB::MYH11 and somatic mitochondrial mutations in acute myeloid leukaemia. | 0 |
| 40931047 | 2025 | Longitudinal single-cell analysis reveals treatment-resistant stem and mast cells with potential treatments for pediatric AML. | 0 |
| 34546543 | 2022 | All-trans retinoic acid induces differentiation in primary acute myeloid leukemia blasts carrying an inversion of chromosome 16. | 0 |
| 28299661 | 2017 | Molecular Basis and Targeted Inhibition of CBFβ-SMMHC Acute Myeloid Leukemia. | 0 |
| 38388794 | 2024 | Clinical implications of additional chromosomal abnormalities in adult acute myeloid leukemia with inv (16)/t(16;16)/CBFB::MYH11. | 0 |
| 42135516 | 2026 | CBFB::MYH11 MRD after the second chemotherapy cycle: a guide for allogeneic transplantation in favorable-risk AML. | 0 |
| 37102302 | 2023 | TP53 and RB1 alterations characterize poor prognostic subgroups in pediatric acute myeloid leukemia. | 0 |
| 31671434 | 2020 | Myeloid Sarcoma With CBFB-MYH11 Fusion (inv(16) or t(16;16)) Prevails in the Abdomen. | 0 |
| 32652328 | 2020 | IL-33/IL1RL1 axis regulates cell survival through the p38 MAPK pathway in acute myeloid leukemia. | 0 |
| 39905935 | 2025 | Clonal dynamics of chronic myelomonocytic leukemia progression: paired-sample comparison. | 0 |
| 35128634 | 2022 | TET2 deficiency cooperates with CBFB-MYH11 to induce acute myeloid leukaemia and represents an early leukaemogenic event. | 0 |
| 36321418 | 2023 | Blast phase of chronic myeloid leukemia with concurrent BCR::ABL1 and SET::NUP214: A report of two cases. | 0 |
| 24002588 | 2014 | CBFB-MYH11/RUNX1 together with a compendium of hematopoietic regulators, chromatin modifiers and basal transcription factors occupies self-renewal genes in inv(16) acute myeloid leukemia. | 0 |
| 34183780 | 2021 | Prognostic values of D816V KIT mutation and peri-transplant CBFB-MYH11 MRD monitoring on acute myeloid leukemia with CBFB-MYH11. | 0 |
| 31612466 | 2020 | Patients aged less than 3 years with acute myeloid leukaemia characterize a molecularly and clinically distinct subgroup. | 0 |
| 41966916 | 2026 | SOHO State of the Art Updates and Next Questions: Is Favorable-risk AML Always Favorable? | 0 |
| 39182671 | 2024 | Tailored Digital PCR Follow-Up of Rare Fusion Transcripts after Initial Detection through RNA Sequencing in Hematological Malignancies. | 0 |
| 30006258 | 2018 | Molecular Minimal Residual Disease Testing in Acute Myeloid Leukemia: A Review for the Practicing Clinician. | 0 |
| 26891877 | 2016 | Leukemogenic potency of the novel FLT3-N676K mutant. | 0 |
| 8751466 | 1996 | The gene product of CBFB-MYH11. | 0 |
| 25635758 | 2015 | Emerging diagnostic and therapeutic approaches in core binding factor acute myeloid leukaemia. | 0 |
| 34674982 | 2022 | Prognostic of Core Binding Factor (CBF) Acute Myeloid Leukemia With Complex Karyotype. | 0 |
| 40293351 | 2025 | Venetoclax plus Modified-Intensity Idarubicin and Cytarabine Treatment as First-Line Treatment for Newly Diagnosed Pediatric Acute Myeloid Leukemia. | 0 |
| 31353165 | 2020 | Detection of a novel CBFB-MYH11 fusion transcript in acute myeloid leukemia M1 with inv(16)(p13q22). | 0 |
| 38447191 | 2024 | A Case of a Patient with Therapy-related Core Binding Factor (CBF) Acute Myeloid Leukemia (CBF-AML). | 0 |
| 39803562 | 2024 | Loss of the Inv(16) Oncogene CBFB::MYH11 Eliminates Leukemia from the Blood and Spleen, but not the Bone Marrow. | 0 |
| 30919505 | 2019 | Measurable residual disease testing for personalized treatment of acute myeloid leukemia. | 0 |
| 39924202 | 2025 | [Therapy-related myeloid neoplasms with inv (16)(p13.1q22);CBFB::MYH11 during treatment for AL amyloidosis]. | 0 |
| 28299658 | 2017 | Clinical Relevance of RUNX1 and CBFB Alterations in Acute Myeloid Leukemia and Other Hematological Disorders. | 0 |
| 30695313 | 2016 | [Case Conference of Hematological Malignancies Based on the Morphology of Blood Cells: Chairmen's Introductory Remarks]. | 0 |
| 41631723 | 2026 | Identification of cellular hierarchy in paediatric acute myeloid leukaemia: The Japan Children's Cancer Group trial (JCCG AML-12). | 0 |
| 21198299 | 2010 | Incidence and prognostic importance of molecular genetic defects in children with acute myeloblastic leukemia. | 0 |
| 28906004 | 2017 | Acute myeloid leukaemia (FAB AML-M4Eo) with cryptic insertion of cbfb resulting in cbfb-Myh11 fusion. | 0 |
| 32492002 | 2020 | [Driver Mutations in Acute Myeloid Leukemia with Inversion of Chromosome 16]. | 0 |
| 37572135 | 2023 | Comparison of efficacy between homoharringtonine, aclarubicin, cytarabine (HAA) and idarubicin, cytarabine (IA) regimens as induction therapy in patients with de novo core binding factor acute myeloid leukemia. | 0 |
| 28735486 | 2017 | Detection and Quantification of Acute Myeloid Leukemia-Associated Fusion Transcripts. | 0 |
| 35531760 | 2022 | Combination of KIT and FLT3-ITD mutation status with minimal residual disease levels guides treatment strategy for adult patients with inv(16) acute myeloid leukemia in first complete remission. | 0 |
| 12239155 | 2002 | Role of Cbfb in hematopoiesis and perturbations resulting from expression of the leukemogenic fusion gene Cbfb-MYH11. | 0 |
| 27468869 | 2016 | Incidence of preleukemic fusion genes in healthy subjects. | 0 |
| 11561156 | 2001 | Function of the inv(16) fusion gene CBFB-MYH11. | 0 |
| 41139231 | 2025 | Optimizing Wilms tumor 1 thresholds for measurable residual disease monitoring in acute myeloid leukemia: Improved sensitivity and concordance with nucleophosmin 1 in a single-center validation study. | 0 |
| 12172539 | 2002 | Altered affinity of CBF beta-SMMHC for Runx1 explains its role in leukemogenesis. | 0 |
| 34674615 | 2021 | Clinical values of gene alterations as marker of minimal residual disease in non-M3 acute myeloid leukemia. | 0 |
| 39659145 | 2025 | Efficacy of Midostaurin Combined With Intensive Chemotherapy in Core Binding Factor Leukemia: A Phase II Clinical Trial. | 0 |
| 30277115 | 2019 | Panoramic view of common fusion genes in a large cohort of Chinese de novo acute myeloid leukemia patients. | 0 |
| 41250875 | 2026 | Genomic and transcriptomic characterization of acute myeloid leukaemia with IL3RA overexpression: Prognostic and therapeutic implications revisited. | 0 |
Article Bibliography
| Pubmed ID | Last Year | Title | Authors |
|---|---|---|---|
| 2779289 | 1989 | Acute nonlymphocytic leukemia with marrow eosinophilia and chromosome 16 abnormality: a report of 18 cases. | Bernard P et al |
| 1453770 | 1992 | Abnormalities of chromosome 16q in myeloid malignancy: 14 new cases and a review of the literature. | Betts DR et al |
| 2069909 | 1991 | Chromosome 16 abnormalities associated with myeloid malignancies. | Campbell LJ et al |
| 8268905 | 1993 | Cloning the breakpoint cluster region of the inv(16) in acute nonlymphocytic leukemia M4 Eo. | Dauwerse JG et al |
| 8338941 | 1993 | Identification of yeast artificial chromosomes containing the inversion 16 p-arm breakpoint associated with acute myelomonocytic leukemia. | Liu P et al |
| 7727763 | 1995 | Molecular pathogenesis of the chromosome 16 inversion in the M4Eo subtype of acute myeloid leukemia. | Liu PP et al |
| 7780153 | 1995 | Heterogeneity in CBF beta/MYH11 fusion messages encoded by the inv(16)(p13q22) and the t(16;16)(p13;q22) in acute myelogenous leukemia. | Shurtleff SA et al |
| 9927211 | 1999 | Genomic acute myeloid leukemia-associated inv(16)(p13q22) breakpoints are tightly clustered. | van der Reijden BA et al |
Summary
Fusion gene
CBFB/MYH11 CBFB (16q22.1) MYH11 (16p13.11) M ins(16)(q22p13p13) ins(16;16)(q22;p13p13) inv(16)(p13q22) t(16;16)(p13;q22)|CBFB/MYH11 CBFB (16q22.1) MYH11 (16p13.11) TIC
Note
the three chromosome anomalies are variants of each other, and they share identical clinical features and genetic pathogenesis

TOP: inv(16)(p13q22) G- banding (left) - Courtesy Jean-Luc Lai and Alain Vanderhaegen; R- banding center bottom: - Courtesy Christiane Charrin, center top and FISH (middle right) - Courtesy Pascale Cornillet-Lefebvre and Stephanie Struski; FISH (right) - Courtesy Hossein Mossafa; commercial FISH probes, split in the inv(16). BOTTOM: t(16;16)(p13;q22) G-banding - left two - Courtesy Diane H. Norback, Eric B. Johnson, and Sara Morrison-Delap, UW Cytogenetic Services; middle two and FSIH Vysis LSI CBFB Dual Color, Break Apart Rearrangement Probe ?nuc ish(CBFBx2)(5CBFB sep 3CBFBx1) - Courtesy Ian Brooks and Jackie Challis, Oncology Cytogenetics, Victorian Clinical Genetics Services, Australia.
Citation
Jean-Loup Huret
inv(16)(p13q22) CBFB/MYH11
t(16;16)(p13;q22) CBFB/MYH11
del(16)(q22) CBFB/MYH11
Atlas Genet Cytogenet Oncol Haematol. 1999-06-01
Online version: http://atlasgeneticsoncology.org/haematological/1036/del(16)(q22)
Historical Card
1997-11-01 inv(16)(p13q22) CBFB/MYH11
t(16;16)(p13;q22) CBFB/MYH11
del(16)(q22) CBFB/MYH11 by Jean-Loup Huret 
Affiliation
Genetics, Dept Medical Information, University of Poitiers, CHU Poitiers Hospital, F-86021 Poitiers, France
